FDA Drugs (New Approvals & NDA)Original article
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program
RegulatoryNeutral
AI Analysis
Summary
The FDA announced the ISTAND Pilot Program to expand drug development tool (DDT) qualification by encouraging development of novel DDT approaches beyond existing programs. This is a routine regulatory initiative with no immediate clinical or commercial implications.
Importance:2/10
Sentiment:
0.00
FDADDTDrug Development ToolISTANDRegulatory ProgramPilot Program
Read the original article
Published by FDA Drugs (New Approvals & NDA) on September 22, 2026 2:59 PM